| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Non-cash lease expense | - | 0 |
| Net loss | -10,198,372 | -7,512,667 |
| Depreciation expense | 6,319 | 5,918 |
| Equity-based compensation | 1,614,793 | 1,141,409 |
| Interest receivable | -25,362 | -19,114 |
| Prepaid expenses | 73,758 | 316,100 |
| Deferred offering costs | 76,393 | 9,416 |
| Other assets | -1,624 | -1,624 |
| Accounts payable | -888,341 | -606,859 |
| Accrued liabilities | -442,941 | -397,580 |
| Net cash used in operating activities | -10,031,707 | -7,674,557 |
| Investment in property and equipment | 5,104 | 3,251 |
| Net cash used in investing activities | -5,104 | -3,251 |
| Proceeds from sale of common stock | 4,015,598 | 3,347,618 |
| Proceeds from exercise of warrants | - | 0 |
| Issuance costs from sale of common stock | 184,647 | 149,019 |
| Proceeds from exercise of stock options | 48,000 | 31,997 |
| Net cash provided by financing activities | 3,878,951 | 3,230,596 |
| Net change in cash and cash equivalents | -6,157,860 | -4,447,212 |
| Cash and cash equivalents at beginning of period | 10,017,942 | - |
| Cash and cash equivalents at end of period | 3,860,082 | - |
Cadrenal Therapeutics, Inc. (CVKD)
Cadrenal Therapeutics, Inc. (CVKD)